Retatrutide’s latest reported weight-loss results (from late-stage trials publicized in late 2025 and May 2026) show very large average weight reductions—up to around ~30% in the highest-dose groups—but also higher discontinuation/side-effect rates than many people expect from earlier “GLP-1” headlines.[1][4]
Most recent headline results (late-stage)
- May 2026 reporting (Eli Lilly trial release): In an 80-week obesity study, reported outcomes included an average loss of ~70.3 lb and 45% of patients on 12 mg losing up to 30% of body weight.[4]
- Dec 2025/late-stage reporting: A 68-week Phase 3 study in people with obesity and knee osteoarthritis reported 28.7% weight loss for the highest dose group who stayed on treatment, and 23.7% when analyzing all treated participants (including those who discontinued).[1]
Why the results come with caveats
- Discontinuation and tolerability: Coverage of the 68-week Phase 3 results noted that side effects were high and many participants discontinued, including some who felt they were losing “too much” weight.[1]
If you tell me what you mean by “latest”
“Latest news” can mean either (a) this year’s press coverage or (b) the newest published trial paper. If you reply with which you want—and whether you care more about obesity without other conditions or obesity plus comorbidities like knee osteoarthritis—I can summarize the newest specific study endpoints (weight %, responder rates, and safety highlights).[4][1]
Sources
The results of the drug are comparable to what is seen with bariatric surgery, according to Eli Lilly.
abcnews.com"Retatrutide delivered powerful weight loss," Leerink Partners analyst David Risinger told investors on Thursday morning. The study's results are the latest signal that retatrutide may be the most effective weight-loss medication in development. As such, retatrutide is a highly anticipated addition to Lilly's (LLY) obesity portfolio, which already includes Zepbound, a weekly GLP-1/GIP shot, and Foundayo, a daily non-peptide GLP-1 pill. It is sometimes referred to as "triple G" because it...
www.morningstar.comThe company’s triple-acting drug retatrutide helped Phase 2 study participants lose a quarter of their body weight, more than what’s been observed in testing of other medicines.
www.biopharmadive.comEli Lilly's next-gen obesity drug delivered major weight loss in a trial, but some patients stopped using it after losing too much weight.
www.statnews.comParticipants of a phase III trial of investigational weight-loss drug retatrutide showed an average weight loss of almost 30% and “substantial” relief from knee osteoarthritis, manufacturer Eli Lilly and Company has announced. In a statement published on 11 December 2025, Eli Lilly reported results from its TRIUMPH-4 trial, which involved 445 participants aged over 18 […]
pharmaceutical-journal.comTransformation videos highlighting crazy weight loss journeys are taking over social media.
www.cbsnews.comA new weight loss injection called retatrutide has shown remarkable results in…
www.diabetes.co.ukFindings demonstrated that participants with obesity lost more than 24% of their starting body weight within 48 weeks of treatment with the highest dose of retatrutide. Additionally, 100% of the participants taking either of the two higher doses (8 mg and 12 mg) lost at least 5% or more of their body weight. The results indicate that retatrutide has an overall safety and tolerability profile similar to other nutrient-stimulated hormone-based therapies, such as GLP-1 receptor agonists approved...
diabetes.org(UPDATED) The once-weekly injectable targeting three hormone receptors hints at “fundamental change” for cardiometabolic disease.
www.tctmd.com